Amer Zeidan: Looking Forward to Sharing New AML Data at ESH 2026
Amer Zeidan, Chief, Division of Hematologic Malignancies; Professor of Medicine at Yale University, shared a post on LinkedIn:
“I look forward to presenting in a podium talk the updated results from our KOMET 007 phase 1/2 study combining the novel oral menin inhibitor ziftomenib with intensive chemotherapy 7+3 in fit patients with newly diagnosed acute myeloid leukemia with NPM1 mutations or KMT2A rearrangements at the European Society of Hematology meeting ESH2026 in Stockholm.
The early results from this study have led to the ongoing registrational-intent and global randomized phase 3 study KOMET 017 of the same combination which I am honored to be the steering committee chair and where at Yale University we were the first center to open and to enroll the first patient globally.”
Stay updated with Hemostasis Today.
-
May 19, 2026, 11:50Nigusu Tesema: What Is Deep Vein Thrombosis and Why Does It Matter After Surgery?
-
May 19, 2026, 11:50Jason Bobay: Highlights Data-Driven DVT Prevention in International Compression Conference
-
May 19, 2026, 11:50Karl Egan: PEDNET Registry Insights Into Inhibitor Development in Severe Haemophilia A
-
May 19, 2026, 11:15Sarah-Anne Nicholas: Excited to Share My First-Author Publication from My PhD Research
-
May 19, 2026, 10:45Jonathan Douxfils: Why Measuring NETosis Remains a Major Challenge in Translational Research
-
May 19, 2026, 10:39Maria Berghs: Rising Demand for Blood Donations in Sickle Cell Care
-
May 19, 2026, 09:38Heghine Khachatryan: Why DVT in Elderly Patients Requires Special Attention?
-
May 19, 2026, 08:52Konstantin Stark: Announcing the Launch of Collaborative Research Center 1784 to Advance Thromboinflammation Research
-
May 19, 2026, 08:35Gokhan Ozdemir: Managing Acute Flow Diverter Stent Thrombosis in a Critical Vertebrobasilar Circulation